Previous Article | Next Article 
Journal of Virology, March 2001, p. 2059-2066, Vol. 75, No. 5
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2059-2066.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Exposure of Hepatitis C Virus (HCV) RNA-Positive
Recipients to HCV RNA-Positive Blood Donors Results in Rapid
Predominance of a Single Donor Strain and Exclusion and/or
Suppression of the Recipient Strain
Tomasz
Laskus,1,*
Lian-Fu
Wang,2
Marek
Radkowski,1,3
Hugo
Vargas,2
Marek
Nowicki,4
Jeffrey
Wilkinson,1 and
Jorge
Rakela1
Division of Transplantation Medicine, Mayo
Clinic Scottsdale, Scottsdale, Arizona 852591;
Division of Gastroenterology and Hepatology, University of
Pittsburgh Medical Center, Pittsburgh, Pennsylvania
152132; Institute of Infectious
Diseases, Medical Academy, Warsaw, Poland3; and
Transfusion Viruses Studies, University of Southern
California, Los Angeles, California 900894
Received 14 July 2000/Accepted 22 November 2000
 |
ABSTRACT |
We have analyzed three cases of hepatitis C virus (HCV)-infected
recipients who received blood from HCV-infected donors. Two recipients
were exposed to two different HCV RNA-positive donors, and one was
exposed to a single donor. All parental genomes from the actual
infecting units of blood and the recipients were defined, and their
presence in the follow-up serum samples was determined using sensitive
strain-specific assays. The strain from one of the donors was found to
predominate in all recipients' serum samples collected throughout the
follow-up period of 10 to 30 months. In two recipients exposed to two
infected donors, the strain from the second donor was occasionally
found at very low level. However, the original recipients' strains
were not detected. Our observations show that HCV-infected individuals
can be superinfected with different strains, and this event may lead to
eradication or suppression of the original infecting strain.
Furthermore, our findings demonstrate that simultaneous exposure to
multiple HCV strains may result in concomitant infection by more than
one strain, although a single strain could rapidly establish its
dominance. The results of the present study suggest the existence of
competition among infecting HCV strains which determines the ultimate
outcome of multiple HCV exposure.
 |
INTRODUCTION |
Hepatitis C virus (HCV) is
recognized as an important cause of chronic hepatitis, cirrhosis, and
hepatocellular carcinoma (2, 15, 28). The overall
prevalence of anti-HCV in the United States is 1.8%, and it is
estimated that 2.7 million Americans carry the virus (1).
One of the unresolved questions associated with HCV infection is the
sequence of events following superinfection with a new HCV strain. It
was found in chimpanzees that persistent infection does not provide
protection against subsequent infection with heterologous and even
homologous strains (9, 22, 23). Occasionally, the
superinfecting strain overtook the original strain (overtake phenomenon) or vice versa; however, the techniques used were not sensitive enough to allow for the detection of strains constituting a
small minority of circulating sequences. Furthermore, the baseline HCV
replication in chimpanzees is typically very low, and it is unclear
whether these findings are relevant for clinical situations.
The evidence that the overtake phenomenon occurs in humans is
limited
in a single case report, the superinfecting strain was only
transiently detected (14). However, in a recently
published study, Eyster et al. (8) reported on a common
change of infecting HCV genotypes over time in high-risk patients with
hemophilia. Although the genotype change was confirmed by direct
sequence analysis of infecting strains in only three cases, these
findings suggest that superinfection could lead to subsequent exclusion of the original infecting strain. However, the dynamics of this process
are unknown, and it is also unclear whether such an overtake is
complete, as the minor strain could replicate at a significantly lower
level than the major strain and thus remain undetectable by routinely
used techniques.
Whether superinfection could result in subsequent concomitant infection
with dual or multiple HCV strains is also unclear. In support of such a
possibility, there are a number of studies reporting the relatively
common detection of various HCV genotypes in the same individual
(21, 25, 26). The parental viral sequences, however, were
not available for analysis in these studies. The evidence, therefore,
is questionable, particularly in light of the reported unreliability of
commonly used genotyping techniques for the detection of mixed
infections (10, 31). It is also likely that some of these
reports described transient dual infections at the time of
superinfection, after which a dominant single infection was
established. Importantly, in several large studies, mixed infections
with various HCV genotypes were found to be extremely rare or
nonexistent (3, 12, 33).
The major obstacle to the study of multiple HCV infections is the lack
of clinical material allowing for unambiguous identification of genomes
to which the persons were exposed. A unique opportunity to study HCV
superinfection in vivo is provided by the Transfusion-Transmitted Viruses Study/National Heart, Lung, and Blood Institute Repository (TTVS/NHLBI). This prospective study of posttransfusion hepatitis was
conducted in the years 1974 to 1981, when HCV was much more prevalent
in the blood donor population. Here we analyze three patients from the
TTVS/NHLBI study who were HCV positive at the time they received a
transfusion of blood from an HCV-infected donor(s). These cases are
unique, as parental genomes from the actual infecting units of blood
and pretransfusion recipients' sera were defined and their presence in
the follow-up recipients' sera was determined by sensitive
strain-specific assays.
 |
MATERIALS AND METHODS |
Recipients and blood donors.
Some clinical, serological, and
virological data on three blood recipients and their respective blood
donors are presented in Table 1. The
female subjects 1 and 2 were enrolled in the TTVS in 1977 and 1978, respectively, when they were hospitalized for genitourinary surgery,
while the male subject 3 was enrolled in 1974, when he was hospitalized
for a cardiosurgical procedure. Prior to transfusion, all subjects were
strongly anti-HCV positive by second-generation enzyme immunoassay
(Ortho Laboratories, Raritan, N.J.) and were HCV RNA positive in serum
by reverse transcriptase (RT)-PCR. Subjects 1 and 2 received blood from
two different HCV RNA-positive donors, while recipient 3 received blood
from a single HCV-infected donor. One of the HCV RNA-positive donors
implicated in transfusion in subject 2 was anti-HCV negative (Table 1). The recipients received 1 U of whole blood from each of their respective donors. For recipients 1 and 2, transfusion from both donors
were administered within hours on the same day. However, the sequence
of transfusion was not recorded in the TTVS database. After
transfusion, recipient 1 became symptomatic by day 35 and continued to
have alanine aminotransferase (ALT) elevations throughout her observed
course (Table 2) and recipient 2 remained
asymptomatic with normal ALT activities, while subject 3 had
intermittent elevations of ALT throughout the observation period (not
shown).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Clinical and virological data for HCV-infected blood
transfusion recipient 1 and her two HCV-infected blood donors
|
|
Donors' serum samples were obtained on the day of donation, while
recipients' pretransfusion samples were collected 1 day before and/or
on the day of transfusion. For patients 1 and 2, the follow-up samples
were collected at 1- to 2-week intervals for the first 10 months, and
for patient 1, additional samples were collected every 3 months for the
next 20 months. However, for patient 3, only sera collected 32, 102, and 327 days after transfusion were available for virological analysis.
All serum samples were kept at
70°C until the present analysis; to
avoid repeat freeze-thawing, they had originally been divided into
250-µl aliquots.
Samples from donors and recipients were tested as part of a coded panel
that included other positive and negative samples as controls. The code
was broken only after all donors' and recipients' samples had their
sequence analyses reported.
RT-PCR.
RNA was extracted from 100 µl of serum by means of
a modified guanidinium thiocyanate-phenol-chloroform technique using a commercially available kit (Ultraspec 3; Biotecx Laboratories, Houston,
Tex.) and was dissolved in 20 µl of water. Ten microliters of this
RNA solution was reverse transcribed with Moloney murine leukemia virus
reverse transcriptase and PCR amplified. For the identification of
virus strains, we have chosen the NS5b region for the following
reasons. (i) It has been reported to be a stable region
(30). Similarly, in our previous study, we observed a minimal number of nucleotide substitutions over time (19).
Importantly, because of this stability, a minimal number of
quasispecies are expected. (ii) The region is sufficiently divergent to
allow for a reliable identification of individual virus strains and is
the basis for genotype classification (27).
For amplification of the NS5 region, we used the following primers:
5' GGCGGAATTCCTGGTCATAGCCTCCGTGAA 3' (nucleotides [nt] 8645 to 8616) and 5' TGGGGATCCCGTATGATACCCGCTGC/TTTC/TGA 3'
(nt 8245 to 8275) for the first round and primers 5'
CGCTTTCACAGATAACGACTAAGT 3' (nt 8580 to 8557) and 5'
CTCCACAGTCACTGAGAGCGACAT 3' (nt 8276 to 8299) for the nested
second round. Subsequently, all PCR products were sequenced directly in
both directions by the Sanger dideoxy chain termination method with a
modified T7 DNA polymerase (Sequenase version 2.0 kit; United States Biochemical).
Extensive measures, described previously (19), were
employed to prevent and detect carryover contamination. All RT-PCR runs included positive controls consisting of end point dilutions of synthetic RNA strands and negative controls included uninfected sera.
The HCV genotypes were determined by direct sequencing of the NS5
region as described elsewhere (19). Quantification of donor sera for HCV RNA was carried out with the Bayer HCV Quantiplex 2.0 assay.
Analysis of E2 region quasispecies.
The E2 region, including
the hypervariable region 1, was amplified as described previously
(17). HCV quasispecies were compared by the single-strand
conformation polymorphism (SSCP) assay as described elsewhere
(19), with minor modifications. This assay is highly
sensitive, as we were routinely able to detect any minor variant
representing
3% of the whole population. In brief, PCR products were
purified with a DNA binding resin system (Wizard PCR; Promega, Madison,
Wis.) and resuspended in 50 µl of water. Next, 2 to 4 µl of the
purified product was diluted in 15 µl of low-ionic-strength solution
(10% saccharose, 0.5% bromophenol blue, 0.5% xylene cyanol),
denatured by heating it at 97°C for 3 min, immediately cooled on ice,
and subjected to nondenaturing 8% polyacrylamide gel electrophoresis
in 1× Tris-borate-EDTA buffer with 400 V applied for 4 to 5 h at
a constant temperature of 25°C. The bands were visualized by silver
staining (Silver Stain; Promega). To lower the risk of artifactual
polymorphism, each analysis was duplicated in an independent experiment
using a new RNA template.
 |
RESULTS |
Prior to transfusion (Table 1 and 2), two different serum samples
from recipient 1 were HCV RNA positive, and the infecting strain was
determined to be genotype 2b. Both her donors were found to be HCV RNA
positive; sequence analysis of the NS5 region revealed that donor A was
infected by genotype 2b, whereas in donor B the infecting viral strain
was type 1a. The earliest posttransfusion serum sample, at day 10, was
HCV RNA positive, but the amplified strain was classified as type 1a
and was closely related to that found in donor B (99.5% similarity).
All subsequent recipient sera were found to have the same type 1a
strain throughout the period recipient 1 was observed. At 913 days
after transfusion, the analyzed NS5 region sequence was identical to
the sequence amplified from serum on day 10 (Fig.
1).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 1.
Nucleotide sequence alignment of the NS5 fragments of
HCV recovered from two blood donors (D) and recipient follow-up sera.
R0, R1, and R2 were recipient sera drawn before and 10 and 913 days
after transfusion, respectively. The sequence recovered from follow-up
recipient serum was closely related to that found in donor B, which is
shown on the top line. Sequence differences between the donor strains
were exploited to design strain-specific primers. Primers A1 and A2
were designed to allow for specific amplification of the type 2b
strains found in the recipient prior to transfusion and the donor A
strain from the background of the donor B and posttransfusion recipient
strains. The underlined sequence segments show the locations of the
strain-specific primers. The nucleotide numbering system follows that
of the type 1a wild-type strain described by Choo et al.
(4).
|
|
Recipient 2 was initially infected by a genotype 2a strain, as was one
of her donors (Table 1); the second donor was infected with genotype
1b. The infecting genotype could not be determined in the earliest
posttransfusion sample, drawn on day 8; however, all subsequent sera
contained a genotype 2a strain whose sequence was virtually identical
to that found in donor B but differed by several nucleotide
substitutions from the recipient's pretransfusion strain.
Recipient 3 and his only donor were both infected with a genotype 1b
strain (Table 1); all three follow-up samples contained a genotype 1b
strain which was 100% identical to that found in the donor but
differed by four nucleotide substitutions from the initial recipient strain.
Strategy to identify minor viral sequences.
In each of the
analyzed cases, the follow-up sera contained HCV strains from one of
the donors; however, the pretransfusion recipients' strains and the
other donors' strains could have been present below the sensitivity
level of direct sequencing (20 to 25%). A commonly used alternative,
sequencing of cloned PCR products, has its own pitfalls, as it may be
vulnerable to the introduction of artifactual polymorphism
(29). Also, to achieve high sensitivity, a large number of
clones have to be processed and sequenced, making it laborious and thus impractical.
We decided to use sequence-specific primers that would allow specific
amplification of one sequence from the background of other sequences.
This strategy takes advantage of the observation that mismatches
localized at the 3' terminus of the primer can dramatically decrease
amplification efficiency (16, 20).
The technique employed is shown in detail for patient 1. First,
strain-specific primers were designed to match type 2b strains from
donor A and the recipient prior to transfusion but to provide a 3'-end
mismatch with respect to the 1a strain found in donor B and in the
recipient posttransfusion (Fig. 1, primers A1 and A2). Thus, these
primers should preferentially amplify both type 2b strains but not the
type 1a strain. To provide the template necessary to optimize the
reactions, viral sequences were amplified with two rounds of universal
primers (see Materials and Methods), and the RT-PCR products were
column purified (Wizard PCR). The approximate number of template copies
was calculated from optical density readings.
Figure 2 illustrates the set-up of PCR
for the specific detection of donor A's and the recipient's
pretransfusion viral sequences (type 2b). As seen in row A, standard
three-step PCR with annealing at 56°C and an MgCl2
concentration of 2.0 mmol allowed for a sensitive and specific
detection of the proper template while the negative control (in this
instance, RT-PCR products from donor B) was not amplified. Next, to
test the sensitivity for the detection of the minor strain from the
background of the major strain, PCR products representing the donor
A-specific sequence were serially diluted in the RT-PCR product of the
donor B strain diluted 1:10 (containing approximately 1010
template copies/µl). As the sensitivity of the assay was now lowered
by approximately 1 log unit, it was theoretically capable of detecting
the minor sequence in the RT-PCR product when the sequence was present
at a concentration of
1:10
8 with respect to the major
sequence. When applied to the detection of the recipient's
pretransfusion strain from the background of donor B's sequence, the
sensitivity of the assay was found to be similar.

View larger version (50K):
[in this window]
[in a new window]
|
FIG. 2.
Optimization of PCR-based detection of donor A's
sequences from the background of donor B's sequences. To provide the
template necessary to optimize the reactions, each NS5 region sequence
was amplified with two rounds of universal primers, and the RT-PCR
products were purified. The number of template copies was calculated
from optical density readings. Subsequent PCRs were done with primers
specific for the donor A and recipient pretransfusion sequences (Fig.
1), while 1 µl of the RT-PCR product of the donor B sequence (diluted
1:10 and containing about 1010 template copies/µl) served
as a negative control (N). Samples were analyzed by agarose gel
electrophoresis (3.5% NuSieve). As seen in gel A, standard three-step
PCR with annealing at 56°C and an MgCl2 concentration of
2.0 mmol provided for a sensitive and specific reaction, detecting 10 copies of the correct template. In the next step, serial dilutions of
the correct template (donor A) were amplified from the background of
1010 template copies of the incorrect (donor B) template.
The sensitivity was lowered by 1 log unit in gel B. Lane m, 1-kbp
molecular ladder (Gibco/BRL). The numbers above the lanes correspond to
the exponents (x) of the template concentrations.
|
|
Detection of minor strains in recipients' sera.
Once its
sensitivity and specificity were determined, the strain-specific assay
was applied to recipient follow-up samples using both round I and II
RT-PCR products (amplified with universal primers) as templates.
Positive reactions were detectable in only one sample collected 56 days
after transfusion (Fig. 3). For
confirmation, this positive reaction was cloned into the TA cloning
vector (Invitrogen), and 10 individual clones were sequenced. Sequence
analysis confirmed that the strain-specific PCR detected the type 2b
sequence. Cloned sequences were more closely related to that found in
donor A than to that found in the recipient prior to transfusion. As
seen in Fig. 4, all unique substitutions
differentiating donor A's strain from the recipient's pretransfusion
strain matched the follow-up samples.

View larger version (73K):
[in this window]
[in a new window]
|
FIG. 3.
Specific detection of the donor A and recipient
pretransfusion sequences in follow-up sera in which the dominant strain
was identified as belonging to donor B (Fig. 1). Extracted RNA
corresponding to 50 µl of serum was subjected to nested RT-PCR, after
which the product was diluted 1:10 and 1 µl was amplified for another
35 cycles with primers specific for the type 2b strains from donor A
and the recipient prior to transfusion. As can be seen, a type 2b
sequence was detected from the background of type 1a sequence in only
one serum sample, which was drawn on day 56 posttransfusion. This
RT-PCR product was cloned and sequenced, and it was determined that it
matched the type 2b sequence from donor A (Fig. 4). The positive
controls (lanes A and R) contained approximately 104
template copies of the correct donor A and recipient
pretransfusion-derived templates, respectively, mixed with
approximately 1010 template copies of the posttransfusion
serum-derived sequence. Lane m, 1-kb molecular ladder (Gibco/BRL).
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 4.
Nucleotide sequence alignment of the NS5 fragments of
HCV recovered from the recipient prior to transfusion (R0) and donor A
[D(A)], and amplified from a follow-up serum sample with primers
specific for type 2b sequences (Fig. 1 and 3). The PCR product was
cloned, after which 10 clones, 4 of which are shown, were sequenced
directly. As can be seen, the latter sequences were more likely to
originate from donor A than from the recipient prior to transfusion.
The underlined sequence fragments show the locations of the
strain-specific primers. The nucleotide numbering system follows that
of the type 1a wild-type strain described by Choo et al.
(4). >>>, sequence unknown.
|
|
To decrease the possibility that these results were influenced by
sampling errors, the assays were repeated starting from extracted RNA.
Next, because the lack of detection of donor A's strain and the
recipient's pretransplant strain in the follow-up samples
hypothetically could have been caused by changes in the viral sequence
primer annealing regions, analogous analysis was repeated using
different sets of primers (both universal and strain specific). Again,
the type 2b sequence was found only in the follow-up sample collected
56 days after transfusion. Analysis of serial dilutions of serum and
RT-PCR products using primers matching the major (donor B) and minor
(donor A) strains revealed that the approximate proportions of the
strains when simultaneously detected in the circulation was
1:10
4.
Similar strain-specific assays were developed and employed for the
analysis of infecting viral strains in the remaining two cases. In
subject 2, the type 1b strain from the second donor (donor A) was
repeatedly detectable in a single follow-up sample collected 300 days
after transfusion. However, it constituted a small minority of the
circulating sequences (
0.1%). A strain-specific assay for the
detection of the recipient 2 pretransfusion strain from the background
of the dominant donor strain could not be successfully developed. To
partially remedy this shortcoming, RT-PCR amplification products from
three different follow-up samples (days 29, 63, and 300) were cloned
into the TA cloning vector (Invitrogen), and 20 individual clones from
each of the reactions were subsequently sequenced. Sequence analysis
confirmed the presence of a type 2a strain which closely matched that
found in donor B, while sequences matching the recipient's
pretransfusion strain were not present. For subject 3, the
pretransfusion recipient strain could not be detected in any of the
analyzed follow-up serum samples.
Figure 5 shows SSCP analysis of the E2
region in patients 1 and 3 (in patient 2, the E2 region could not be
amplified). As can be seen, the evolution of viral quasispecies was
clearly different in the two cases. In patient 1, the number of major
variants within quasispecies decreased after transfusion compared to
the pretransfusion sample, and the quasispecies composition remained
unchanged for the observation period. In contrast, in patient 3, the
number of major variants increased, and the quasispecies showed
constant evolution during the follow up.

View larger version (74K):
[in this window]
[in a new window]
|
FIG. 5.
Analysis by SSCP of the E2 region (including the
hypervariable region 1) of HCV in two HCV-positive transfusion
recipients who received HCV-infected blood and in whom the donor strain
became predominant after transfusion. Viral sequences were amplified
from follow-up samples and compared to recipient pretransfusion (R) and
donor (D) sequences. As can be seen, the number of major variants
within quasispecies in patient (Pt) 1 decreased after transfusion
compared to the pretransfusion sample, and the quasispecies composition
remained unchanged during the observation period. In contrast, the
number of major variants increased in patient 3, and the quasispecies
composition showed constant evolution during the follow-up. mo,
months.
|
|
 |
DISCUSSION |
In the present study, we have shown that after exposure of
HCV-positive recipients to one or two blood donors, the original recipients' strains became undetectable while all donor strains established infection in the recipient. However, one donor strain was
clearly predominant, while the other was detected only occasionally. These observations documenting the predominance of a single strain after superinfection are compatible with the results of our recent study on the outcome of liver transplantation in HCV-infected patients
who received HCV-infected grafts (19, 32). In that study,
analysis of sequential follow-up sera revealed that half of the
patients retained their original HCV infecting strain while in the
other half the donor strain took over. However, as the study was
conducted with severely immunosuppressed liver transplant recipients
and the viral load transplanted with the graft was exceedingly large,
it is unclear whether this observation would be pertinent to other
clinical situations.
The observed predominance of one strain could perhaps be explained from
the evolutionary point of view. The major hypothesis of classical
population biology, the competitive exclusion principle, states that in
the absence of niche differentiation, one competing species will
eventually eliminate or exclude the other (11). HCV is a
rapidly replicating virus (37), and even small fitness differences, understood as the overall replication and survival ability, could result in overgrowth of one strain by another. The
applicability of the competitive exclusion principle to RNA virus
populations in cell culture is highly likely, as it has been
demonstrated that even virus populations of approximately equal fitness
are inherently unstable, since stochastic changes in the balance do
eventually occur due to the sudden evolution of higher-fitness variants
(5). Presumably, such a displacement of one virus
population by another could also occur in infected animals and humans;
however, in the case of an infected host, the equilibrium is infinitely
more complex, and any shift in the virus population(s) might be
mitigated by changes in the adaptive environment.
One theoretical way to prevent competitive exclusion is the development
of a parasitic relationship, where one virus population adapts to use
the resources of another virus population and in this way compensates
for fitness disadvantages; the end result is the development of an
equilibrium. Well-known example of such a relationship are "defective
interfering particles," described for many human and animal viruses
(13) and recently also for HCV (24). An
intriguing possibility is that the minor strain was more adept at
infecting certain cells within the liver or even in extrahepatic sites.
For example, it has been demonstrated for lymphocytic choriomeningitis
virus that strains differing by a single amino acid substitution, when
inoculated together into a mouse, are competitively selected either by
the liver and spleen or by neurons (6). In light of recent
findings (17, 18), the presence of extrahepatic HCV
replication is highly likely. Nevertheless, regardless of the
mechanisms that allowed the minor strain to survive, their
effectiveness was probably limited, as it was detectable only
transiently and constituted a small fraction of the circulating virus population.
Whether the immune system has played any role in the selection of
infecting strains is unclear. It can be argued that the superinfecting
strain is immunologically favored, as it represents, to a certain
extent, an "escape mutant." However, neither in our previous study
of liver transplant recipients (19, 32) nor in published
chimpanzee studies (9, 22, 23) did the donor strains seem
to be privileged in any way, which suggests the likely role of viral
factors, such as the replication fitness of individual strains, in
establishing dominance in superinfection and coinfection.
Patients 1 and 2 received blood from two infected donors. While both
donor strains established infection in the recipient, one was clearly
predominant. What determined this strain predominance is unclear,
although one possibility is the size of the inoculum. Interestingly, in
case 1, the predominant strain was the one with the higher viral load
in the donor. However, in both donors in case 2, the levels of viremia
were below the sensitivity limit of the quantification assay. Whether
the amount of virus introduced during transfusion determines the
outcome of superinfection is unclear, as in all three analyzed cases
the donor strain overtook the recipient strain. In any case, the
overall amount of virus in the recipient, taking into account the
amount of virus in body fluids and the liver, must have been much
larger than the amount transfused in 1 U of blood.
The E2 region quasispecies analysis provided the opportunity to study
the evolution of quasispecies of two different HCV strains in the same
host. Interestingly, two different pictures emerged: in patient 1, the
number of viral variants within quasispecies was reduced and the
quasispecies composition remained largely unchanged during the follow
up, while in patient 3 the number of variants increased after the
superinfection and quasispecies showed constant evolution thereafter.
These observations suggest that the interplay between different HCV
strains and hosts may result in different, perhaps unique, quasispecies
compositions. This is compatible with the assumption that at any given
moment during the natural history of the infection, the quasispecies distribution represents the best-fitting population that has
established a status of equilibrium with a particular host
(7).
Studies of superinfection and coinfection phenomena have important
practical implications, as repeated exposure to HCV is common in
high-risk groups, such as drug addicts, but is also likely in many
other epidemiological settings. Furthermore, detailed analysis of
virological outcome in situations where more than one viral strain is
involved, and particularly the evidence for eradication of one strain
by another, could have implications for novel treatment options or for
the development of a live, attenuated vaccine. The feasibility of
exploiting viral interference for antiviral therapy has been
demonstrated for influenza A virus infections. An attenuated
cold-adapted influenza virus was shown to block the growth of wild-type
virus in vitro (34) and, when administered to infected
animals or humans, would prevent or reduce the disease symptoms
(35, 36).
In summary, we have described three cases of blood transfusion from
HCV-positive donors into HCV-positive recipients. In each case, the
recipient's pretransfusion strain was apparently displaced by a
predominant strain from the transfused blood. In both patients exposed
to two HCV RNA-positive donors, the second donor's strain also
produced infection. These observations are compatible with the presence
of direct competition between infecting strains, which could result in
the dominance of a single strain and the competitive exclusion or
suppression of other strains.
 |
ACKNOWLEDGMENTS |
The formation of the TTVS/NHLBI Repository was supported by
contract no. NO1-HB-42972 of the National Institutes of Health. The
study was supported by a grant from The Sigismunda Palumbo Foundation.
Sera were provided by James W. Mosley, University of Southern
California, Luiz H. Barbosa, and George J. Nemo, Division of Blood
Diseases and Resources.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: SC Johnson Bldg.
Sj-3, Mayo Clinic Scottsdale, 13400 East Shea Blvd., Scottsdale, AZ 85259. Phone: (480) 301-6370. Fax: (480) 301-3384. E-mail:
laskus.tomasz{at}mayo.edu.
 |
REFERENCES |
| 1.
|
Alter, M. J.,
D. Kruszon-Moran,
O. V. Nainan,
G. M. McQuillan,
F. Gao,
L. A. Moyer,
R. A. Kaslow, and H. S. Margolis.
1999.
The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
N. Engl. J. Med.
341:556-562[Abstract/Free Full Text].
|
| 2.
|
Alter, M. J.,
H. S. Margolis,
K. Krawczynski,
F. N. Judson,
A. Mares,
W. J. Alexander,
P. Y. Hu,
J. K. Miller,
M. A. Gerber,
R. E. Sampliner,
E. L. Meeks, and M. J. Beach.
1992.
The natural history of community-acquired hepatitis C in the United States. The Sentinel Counties Chronic non-A, non-B Hepatitis Study Team.
N. Engl. J. Med.
327:1899-1905[Abstract].
|
| 3.
|
Bernier, L.,
B. Willems,
G. Delage, and D. G. Murphy.
1996.
Identification of numerous hepatitis C virus genotypes in Montreal, Canada.
J. Clin. Microbiol.
34:2815-2818[Abstract].
|
| 4.
|
Choo, Q. L.,
K. H. Richman,
J. H. Han,
K. Berger,
C. Lee,
C. Dong,
C. Gallegos,
D. Coit,
R. Medina-Selby,
P. J. Barr,
A. J. Weiner,
D. W. Bradley,
G. Kuo, and M. Houghton.
1991.
Genetic organization and diversity of the hepatitis C virus.
Proc. Natl. Acad. Sci. USA
88:2451-2455[Abstract/Free Full Text].
|
| 5.
|
Clarke, D. K.,
E. A. Duarte,
S. F. Elena,
A. Moya,
E. Domingo, and J. Holland.
1994.
The red queen reigns in the kingdom of RNA viruses.
Proc. Natl. Acad. Sci. USA
91:4821-4824[Abstract/Free Full Text].
|
| 6.
|
Dockter, J.,
C. F. Evans,
A. Tishon, and M. B. Oldstone.
1996.
Competitive selection in vivo by a cell for one variant over another: implications for RNA virus quasispecies in vivo.
J. Virol.
70:1799-1803[Abstract].
|
| 7.
|
Domingo, E.,
E. Martinez-Salas,
F. Sobrino,
J. C. de la Torre,
A. Portela,
J. Ortin,
C. Lopez-Galindez,
P. Perez-Brena,
N. Villanueva,
R. Najera,
S. VandePol,
D. Steinhauer,
N. DePolo, and J. Holland.
1985.
The quasispecies (extremely heterogeneous) nature of viral RNA genome populations: biological relevance a review.
Gene
40:1-8[CrossRef][Medline].
|
| 8.
|
Eyster, M. E.,
K. E. Sherman,
J. J. Goedert,
A. Katsoulidou, and A. Hatzakis.
1999.
Prevalence and changes in hepatitis C virus genotypes among multitransfused persons with hemophilia. The Multicenter Hemophilia Cohort Study.
J. Infect. Dis.
179:1062-1069[CrossRef][Medline].
|
| 9.
|
Farci, P.,
H. J. Alter,
S. Govindarajan,
D. C. Wong,
R. Engle,
R. R. Lesniewski,
I. K. Mushahwar,
S. M. Desai,
R. H. Miller,
N. Ogata, and R. H. Purcell.
1992.
Lack of protective immunity against reinfection with hepatitis C virus.
Science
258:135-140[Abstract/Free Full Text].
|
| 10.
|
Forns, X.,
M. D. Maluenda,
F. X. Lopez-Labrador,
S. Ampurdanes,
E. Olmedo,
J. Costa,
P. Simmonds,
J. M. Sanchez-Tapias,
M. T. Jimenez De Anta, and J. Rodes.
1996.
Comparative study of three methods for genotyping hepatitis C virus strains in samples from Spanish patients.
J. Clin. Microbiol.
34:2516-2521[Abstract].
|
| 11.
|
Gause, G. F.
1971.
The struggle for existence.
Dover Publications, New York, N.Y.
|
| 12.
|
Guadagnino, V.,
T. Stroffolini,
M. Rapicetta,
A. Costantino,
L. A. Kondili,
F. Menniti-Ippolito,
B. Caroleo,
C. Costa,
G. Griffo,
L. Loiacono,
V. Pisani,
A. Foca, and M. Piazza.
1997.
Prevalence, risk factors, and genotype distribution of hepatitis C virus infection in the general population: a community-based survey in southern Italy.
Hepatology
26:1006-1011[CrossRef][Medline].
|
| 13.
|
Huang, A. S., and D. Baltimore.
1970.
Defective viral particles and viral disease processes.
Nature
226:325-327[CrossRef][Medline].
|
| 14.
|
Kao, J. H.,
P. J. Chen,
M. Y. Lai, and D. S. Chen.
1993.
Superinfection of heterologous hepatitis C virus in a patient with chronic type C hepatitis.
Gastroenterology
105:583-587[Medline].
|
| 15.
|
Kiyosawa, K.,
T. Sodeyama,
E. Tanaka,
Y. Gibo,
K. Yoshizawa,
Y. Nakano,
S. Furuta,
Y. Akahane,
K. Nishioka,
R. H. Purcell, and H. J. Alter.
1990.
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus.
Hepatology
12:671-675[Medline].
|
| 16.
|
Kwok, S.,
D. E. Kellogg,
N. McKinney,
D. Spasic,
L. Goda,
C. Levenson, and J. J. Sninsky.
1990.
Effects of primer-template mismatches on the polymerase chain reaction: human immunodeficiency virus type 1 model studies.
Nucleic Acids Res.
18:999-1005[Abstract/Free Full Text].
|
| 17.
|
Laskus, T.,
M. Radkowski,
L. F. Wang,
M. Nowicki, and J. Rakela.
2000.
Uneven distribution of hepatitis C virus quasispecies in tissues from subjects with end-stage liver disease: confounding effect of viral adsorption and mounting evidence for the presence of low-level extrahepatic replication.
J. Virol.
74:1014-1017[Abstract/Free Full Text].
|
| 18.
|
Laskus, T.,
M. Radkowski,
L. F. Wang,
H. Vargas, and J. Rakela.
1998.
Search for hepatitis C virus extrahepatic replication sites in patients with acquired immunodeficiency syndrome: specific detection of negative- strand viral RNA in various tissues.
Hepatology
28:1398-1401[CrossRef][Medline].
|
| 19.
|
Laskus, T.,
L. F. Wang,
J. Rakela,
H. Vargas,
A. D. Pinna,
A. C. Tsamandas,
A. J. Demetris, and J. Fung.
1996.
Dynamic behavior of hepatitis C virus in chronically infected patients receiving liver graft from infected donors.
Virology
220:171-176[CrossRef][Medline].
|
| 20.
|
Nassal, M., and A. Rieger.
1990.
PCR-based site-directed mutagenesis using primers with mismatched 3'-ends.
Nucleic Acids Res.
18:3077-3078[Free Full Text].
|
| 21.
|
Nousbaum, J. B.,
S. Pol,
B. Nalpas,
P. Landais,
P. Berthelot, and C. Brechot.
1995.
Hepatitis C virus type 1b (II) infection in France and Italy. Collaborative Study Group.
Ann. Intern. Med.
122:161-168[Abstract/Free Full Text].
|
| 22.
|
Okamoto, H.,
S. Mishiro,
H. Tokita,
F. Tsuda,
Y. Miyakawa, and M. Mayumi.
1994.
Superinfection of chimpanzees carrying hepatitis C virus of genotype II/1b with that of genotype III/2a or I/1a.
Hepatology
20:1131-1136[CrossRef][Medline].
|
| 23.
|
Prince, A. M.,
B. Brotman,
T. Huima,
D. Pascual,
M. Jaffery, and G. Inchauspe.
1992.
Immunity in hepatitis C infection.
J. Infect. Dis.
165:438-443[Medline].
|
| 24.
|
Prince, A. M.,
T. Huima-Byron,
T. S. Parker, and D. M. Levine.
1996.
Visualization of hepatitis C virions and putative defective interfering particles isolated from low-density lipoproteins.
J. Viral Hepat.
3:11-17[Medline].
|
| 25.
|
Ravaggi, A.,
A. Rossini,
C. Mazza,
M. Puoti,
M. G. Marin, and E. Cariani.
1996.
Hepatitis C virus genotypes in northern Italy: clinical and virological features.
J. Clin. Microbiol.
34:2822-2825[Abstract].
|
| 26.
|
Sheng, L.,
M. Willems,
K. Peerlinck,
J. Vermylen, and S. H. Yap.
1995.
Hepatitis C virus genotypes in Belgian hemophiliacs.
J. Med. Virol.
45:211-214[Medline].
|
| 27.
|
Simmonds, P.,
E. C. Holmes,
T. A. Cha,
S. W. Chan,
F. McOmish,
B. Irvine,
E. Beall,
P. L. Yap,
J. Kolberg, and M. S. Urdea.
1993.
Classification of hepatitis C virus into six major genotypes and a series of subtypes by phylogenetic analysis of the NS-5 region.
J. Gen. Virol.
74:2391-2399[Abstract/Free Full Text].
|
| 28.
|
Simonetti, R. G.,
C. Camma,
F. Fiorello,
M. Cottone,
M. Rapicetta,
L. Marino,
G. Fiorentino,
A. Craxi,
A. Ciccaglione,
R. Giuseppetti,
T. Stroffolini, and L. Pagliaro.
1992.
Hepatitis C virus infection as a risk factor for hepatocellular carcinoma in patients with cirrhosis. A case-control study.
Ann. Intern. Med.
116:97-102.
|
| 29.
|
Smith, D. B.,
J. McAllister,
C. Casino, and P. Simmonds.
1997.
Virus `quasispecies': making a mountain out of a molehill?
J. Gen. Virol.
78:1511-1519[Medline].
|
| 30.
|
Sullivan, D. G.,
J. J. Wilson,
R. L. Carithers, Jr.,
J. D. Perkins, and D. R. Gretch.
1998.
Multigene tracking of hepatitis C virus quasispecies after liver transplantation: correlation of genetic diversification in the envelope region with asymptomatic or mild disease patterns.
J. Virol.
72:10036-10043[Abstract/Free Full Text].
|
| 31.
|
Toniutto, P.,
M. Pirisi,
S. G. Tisminetzky,
C. Fabris,
E. Chinellato,
M. Gerotto,
E. Falleti,
P. Ferroni,
T. Lombardelli,
E. Bartoli, and F. Baralle.
1996.
Discordant results from hepatitis C virus genotyping by procedures based on amplification of different genomic regions.
J. Clin. Microbiol.
34:2382-2385[Abstract].
|
| 32.
|
Vargas, H. E.,
T. Laskus,
L. F. Wang,
R. Lee,
M. Radkowski,
F. Dodson,
J. J. Fung, and J. Rakela.
1999.
Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts.
Gastroenterology
117:149-153[CrossRef][Medline].
|
| 33.
|
Vargas, H. E.,
L. F. Wang,
T. Laskus,
A. Poutous,
R. Lee,
A. Demetris,
F. Dodson,
A. Casavilla,
J. Fung,
T. Gayowski,
N. Singh,
I. Marino, and J. Rakela.
1997.
Distribution of infecting hepatitis C virus genotypes in end-stage liver disease patients at a large American transplantation center.
J. Infect. Dis.
175:448-450[Medline].
|
| 34.
|
Whitaker-Dowling, P.,
W. Lucas, and J. S. Youngner.
1990.
Cold-adapted vaccine strains of influenza A virus act as dominant negative mutants in mixed infections with wild-type influenza A virus.
Virology
175:358-364[CrossRef][Medline].
|
| 35.
|
Whitaker-Dowling, P.,
H. F. Maassab, and J. S. Youngner.
1991.
Dominant-negative mutants as antiviral agents: simultaneous infection with the cold-adapted live-virus vaccine for influenza A protects ferrets from disease produced by wild-type influenza A.
J. Infect. Dis.
164:1200-1202[Medline].
|
| 36.
|
Youngner, J. S.,
J. J. Treanor,
R. F. Betts, and P. Whitaker-Dowling.
1994.
Effect of simultaneous administration of cold-adapted and wild-type influenza A viruses on experimental wild-type influenza infection in humans.
J. Clin. Microbiol.
32:750-754[Abstract/Free Full Text].
|
| 37.
|
Zeuzem, S.,
J. M. Schmidt,
J. H. Lee,
B. Ruster, and W. K. Roth.
1996.
Effect of interferon alfa on the dynamics of hepatitis C virus turnover in vivo.
Hepatology
23:366-371[Medline].
|
Journal of Virology, March 2001, p. 2059-2066, Vol. 75, No. 5
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.5.2059-2066.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Wang, X.-H., Netski, D. M., Astemborski, J., Mehta, S. H., Torbenson, M. S., Thomas, D. L., Ray, S. C.
(2007). Progression of Fibrosis during Chronic Hepatitis C Is Associated with Rapid Virus Evolution. J. Virol.
81: 6513-6522
[Abstract]
[Full Text]
-
Roque-Afonso, A.-M., Ducoulombier, D., Di Liberto, G., Kara, R., Gigou, M., Dussaix, E., Samuel, D., Feray, C.
(2005). Compartmentalization of Hepatitis C Virus Genotypes between Plasma and Peripheral Blood Mononuclear Cells. J. Virol.
79: 6349-6357
[Abstract]
[Full Text]
-
Radkowski, M., Bednarska, A., Horban, A., Stanczak, J., Wilkinson, J., Adair, D. M., Nowicki, M., Rakela, J., Laskus, T.
(2004). Infection of primary human macrophages with hepatitis C virus in vitro: induction of tumour necrosis factor-{alpha} and interleukin 8. J. Gen. Virol.
85: 47-59
[Abstract]
[Full Text]
-
Laskus, T., Radkowski, M., Bednarska, A., Wilkinson, J., Adair, D., Nowicki, M., Nikolopoulou, G. B., Vargas, H., Rakela, J.
(2002). Detection and Analysis of Hepatitis C Virus Sequences in Cerebrospinal Fluid. J. Virol.
76: 10064-10068
[Abstract]
[Full Text]
-
de la Fuente, J., Garcia-Garcia, J. C., Blouin, E. F., Saliki, J. T., Kocan, K. M.
(2002). Infection of Tick Cells and Bovine Erythrocytes with One Genotype of the Intracellular Ehrlichia Anaplasma marginale Excludes Infection with Other Genotypes. CVI
9: 658-668
[Abstract]
[Full Text]
-
Radkowski, M., Wilkinson, J., Nowicki, M., Adair, D., Vargas, H., Ingui, C., Rakela, J., Laskus, T.
(2002). Search for Hepatitis C Virus Negative-Strand RNA Sequences and Analysis of Viral Sequences in the Central Nervous System: Evidence of Replication. J. Virol.
76: 600-608
[Abstract]
[Full Text]